• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British journal of neurosurgery >The role of magnetic resonance-guided laser ablation in neurooncology
【24h】

The role of magnetic resonance-guided laser ablation in neurooncology

机译：磁共振引导激光消融在神经肿瘤学中的作用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction. The use of magnetic resonance-guided laser-induced thermal therapy (MR-LITT) as a minimally invasive method of treating intra-cranial pathology is a rapidly growing field. The use of MR-LITT in neurooncology has shown promising results; however, there has been no review to date of the current literature. Methods. A review of the published literature regarding MR-LITT in neurooncology was performed. Studies on PubMed were included if at least one patient with a cerebral tumour or radiation necrosis was treated using quantitative MR thermography-guided LITT, as well as if either safety or outcomes were discussed. Results. In treating recurrent Grade-III and -IV gliomas, we found improved median overall survival of 20.9 months from diagnosis of recurrence, which is comparable with that of 18.9 months for high-dose-rate brachytherapy and 24.4 months for repeated open surgery. Median progression-free survival (PFS) of recurrent glioma is noted to be 4.5 months. For metastatic lesions, we found a median overall survival (OS) to vary between 9.0 and 19.8 months with a PFS between 3.8 and 8.5 months. Current literature reports median OS in similar patients to lie between 7.0 and 28.6 months. Severe complication rates (with permanent deficits) are found to be between 12 and 16.7%, comparable with 11% found in literature for open surgery. Conclusions. The current literature shows that MR-LITT is safe and shows promising local tumour control rates. Larger randomised studies are warranted to further investigate this adjuvant therapy in the treatment of recurrent high-grade gliomas and metastases.
机译：介绍。磁共振引导激光诱导热疗法（MR-LITT）作为治疗颅内病理的微创方法的使用正在迅速发展。 MR-LITT在神经肿瘤学中的应用已显示出可喜的结果。然而，迄今为止，尚未对现有文献进行审查。方法。回顾了有关神经肿瘤学中MR-LITT的文献。如果至少一名患有脑肿瘤或放射坏死的患者使用定量MR热像仪引导的LITT进行治疗，以及是否讨论了安全性或结果，则应包括PubMed研究。结果。在治疗复发的III级和-IV级神经胶质瘤中，我们发现从复发诊断中获得的平均中位生存期改善了20.9个月，这与高剂量近距离放疗的18.9个月和重复开放手术的24.4个月相当。复发性神经胶质瘤的中位无进展生存期（PFS）为4.5个月。对于转移性病变，我们发现中位总生存期（OS）在9.0到19.8个月之间变化，PFS在3.8到8.5个月之间。当前文献报道类似患者的中位OS在7.0至28.6个月之间。严重并发症发生率（永久性缺陷）在12％至16.7％之间，与开放手术文献中发现的11％相当。结论当前文献表明，MR-LITT是安全的，并且显示出有希望的局部肿瘤控制率。有必要进行更大范围的随机研究以进一步研究这种辅助疗法在复发性高级别神经胶质瘤和转移瘤的治疗中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号